Healthcare

Global Erythropoiesis Stimulating Agents Market

January 10, 2020
ID: SR/HC-02
Format:Pdf
Pages:220

Global Erythropoiesis Stimulating Agents Market by Product Type (Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Epoetin-Theta and Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta), By Application (Cancer, Renal Disorders, Anti-retroviral Treatment, Neural diseases and Others),By Distribution Channel (Offline Channel and Online Channel) and By Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa)

Description

Global Erythropoiesis Stimulating Agents Market Overview

Erythropoietin in the human body is a hormone like substance secreted by the kidneys and liver, which can promote red blood cell production. Erythropoietin can increase blood flow specific solubility (increase the percentage of red blood cells in the blood) in patients with kidney disease anemia. EPO stimulants are artificially synthesized based on the principle of erythropoietin, which can promote the generation of oxygen in muscles, thereby making muscles stronger and working longer. Agents promoting the synthesis of red blood cells are known as erythropoiesis stimulating agents.

Erythropoiesis stimulating agents recommended for the treatment of anemia. Erythropoietin (EPO) is an essential hematopoietic growth factor for red blood cell proliferation, differentiation, and maintenance of standard numbers of peripheral circulating red blood cells in the body.

Global Erythropoiesis Stimulating Agents Market Insights

Global Erythropoiesis Stimulating Agents Market expected to grow with a CAGR of 10.3% during the predicted period, 2019-2027, and projected to generate revenue over USD 12.5 Billion by 2020. The rise in the incidence of anemia cases worldwide is likely to robust the growth of the global Erythropoiesis Stimulating Agents market in the estimated period. Additionally, the rising awareness about erythropoiesis stimulating agent therapies across the globe leads to the growth of the global Erythropoiesis Stimulating Agents market. Moreover, the surge in demand for efficient drugs to control the effects of impaired production of the molecule erythropoietin is estimated to drive the global Erythropoiesis Stimulating Agents market in the upcoming periods.

As per the World Health Organization, anemia is among the several complications of chronic kidney disease, with a prevalence of about 15% in the United States. More than 50% of patients with advanced disease develop anemia. Further, the growing incidence of chronic kidney disease worldwide is propelling an exponential growth in the global Erythropoiesis Stimulating Agents market in the future timeline. According to WHO 2015 study estimated that 1.2 million people died from kidney failure, an increase of 32% since 2005. Additionally, each year, around 1.7 million people die from acute kidney injury. Overall, about 5–10 million people die annually from kidney disease.

Besides, an increase in the number of new cancer cases and the rapid surge in tumor disease expected to accelerate the global Erythropoiesis Stimulating Agents market. The World Health Organization expects the number of cases related to cancer will increase by 70%, from 14 million in 2012 to 18.1 million in 2018 and 24 million by 2035.

Growth Driver

The increasing number of patients suffering from anemic condition induced due to cancer, HIV, and kidney failures

The global incidence of chronic kidney disease has increased dramatically, and chronic kidney disease has become a public health problem across the globe. Changes in age and epidemiological trends have significantly increased the incidence of chronic kidney disease worldwide. According to WHO, the global prevalence of chronic kidney disease (CKD) increased by 88.76%, the prevalence increased by 86.95%, and deaths.

A rising number of cancer patients and the surge in the incidence of tumor-related anemia

The increasing number of new cancer cases and prolonging survival time will increase the number of patients. Globally, malignant tumors are a threat to human health. The incidence of tumor-associated anemia is as high as 60% Cancer-related anemia (CRA). Anemia that occurs during development and treatment is one of the common concomitant diseases of malignant tumors.

Rising awareness about erythropoiesis stimulating agent therapies

Erythropoiesis Stimulating Agents increase the number of red blood cells, used for anemia, tissue separation, premature babies, used in cancer and hematology. The demand for erythropoiesis stimulating agents is rapidly increasing due to the rising prevalence of chronic kidney disease, cancer, and the growing demand for cheaper erythropoietin drugs.

Product Type Segmental Analysis

Based on Product Type, the global Erythropoiesis Stimulating Agents Market categorized into Epoetin Alfa, Epoetin Beta, Darbepoetin Alfa, Epoetin-Theta, and Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta). The Epoetin Alfa segment projected to lead the market, owing to the augmentation in demand of Epoetin Alfa for treatment of anemia (low red blood cell count) in people with chronic kidney failure, and people are receiving chemotherapy. Darbepoetin Alfa will drive by more number of approved products for prescription in this segment in comparison to others for anemia caused by renal disorders.

Application Segmental Analysis

Based on the Application, the Global Erythropoiesis Stimulating Agents Market classified into Cancer, Renal Disorders, Anti-retroviral Treatment, Neural diseases, and others. The Cancer segment anticipated to dominate the market as the patients with cancer-related anemia is commonly prescribed by erythropoietin in the form of epoetin alfa and epoetin beta. Renal Disorders segment will grow by renal anemia, which predominantly rises due to relative erythropoietin (EPO) deficiency.

Distribution Channel Segmental Analysis

Based on the distribution channel, the Global Erythropoiesis Stimulating Agents Market segmented into Offline Channel and Online Channel. The Offline Channel segment will dominate the market due to population, which is still dependent on conventional distribution channels such as pharmacies at the hospital, ambulatory surgical centers, and retail pharmacies. Online Channels will drive by the rising number of internet users and the availability of online platforms to purchase pharmaceutical products.

Region Segmental Analysis

Based on geography, the global Erythropoiesis Stimulating Agents market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America expected to dominate the market attributed to the availability of effective treatments for various chronic diseases, like cancer, chronic kidney disease (CKD), neural, and HIV infections, along with increasing investments in the R&D activities from both government and private entities. According to the CDC, in 2016, about 29 million people had diabetes, while about 86 million were in the pre-diabetic stage.

The European market will drive by the emerging economies and new products with better efficacy, which will be a significant opportunity for the erythropoietin stimulating agents market.

Competitor Analysis

Companies such as Biocon, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals, Amgen Inc., Hoffmann-La Roche, Biosidus, Thermo Fisher Scientific, F. Hoffmann La Roche, Pfizer, and Ranbaxy Laboratories Ltd are the key players in the Global Erythropoiesis Stimulating Agents Market.

Key Stakeholders

Market research and consulting firms
Industry associations
Global Erythropoiesis Stimulating Agents Service Providers
Research organizations and consulting companies
Organizations, associations, and alliances related to Erythropoiesis-Stimulating Agents
Regulatory bodies

Scope of the report

Report Attribute	Details
Market size value in 2020	USD 12.5 Billion
Revenue forecast in 2027	USD 20.3 Billion
Growth Rate	CAGR of 10.30% from 2020 to 2027
Historical data	2017-2019
Forecast period	2021 – 2027
Region covered	North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key companies Profiled	Biocon, Johnson & Johnson, F. Hoffmann La Roche, Pfizer, Intas Pharmaceuticals, Amgen Inc., Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., Biosidus, Thermo Fisher Scientific, and Ranbaxy Laboratories Ltd.

Recent Developments

In September 2021, Luspatercept received marketing authorization through the European Union (EU) for the treatment of patients with myelodysplastic syndrome (MDS) or transfusion-dependent beta-thalassemia (BT).
In August 2021, Dosis expanded its kidney care platform with Iron Advisor Tool to personalize anemia management.
In August 2021, The European Commission (EC) approved Astellas’ Evrenzo™ for the treatment of chronic kidney disease-related anemia.

The objective of the Research

Market Modelling Market modeling starts with identifying a target market where historical data exists. A Market can include prediction problems, economic factors, analyzing customer behavior, and identifying new patterns from past events, which helps our client to have deep dive into the market.
Product Analysis Product analysis involves steps such as examining product features, costs, availability, quality, and other aspects. Product analysis is conducted to understand potential buyers and measure competition in the market.
Market Trend and Economic Factors Analysis This analysis helps in assessing potential changes to an economy’s inflation rate, taxes, interest rates, exchange rates, trading regulations, and excise duties that can or have a major effect on the target market.
Market Segmental Analysis Segmental analysis defines in-depth scenario of the target market by the process of grouping consumers into naturally existing created segments of consumers who share similar product preferences or characteristics
Geographical Mapping The geographical mapping approach helps our clients to understand national or international markets because different consumers in different regions have different needs wants, and cultural characteristics that can be specifically targeted.

Market Modelling

By Product Type

Epoetin Alfa
Epoetin Beta
Darbepoetin Alfa
Epoetin-Theta
Others (Epoetin-Zeta, Epoetin-Omega, Epoetin-Lambda, Epoetin-Delta)

By Application

Cancer
Renal Disorders
Anti-retroviral Treatment
Neural diseases
Others

By Distribution Channel

Offline Channel
Online Channel

By Region

North America
Europe
Asia Pacific
South America
Middle East & Africa

Table Of Contents

Methodology

Request Sample

Frequently Asked Questions (FAQ):

What does an erythropoiesis-stimulating agent mean?

Erythropoiesis Stimulating Agents is a substance secreted by the kidneys and liver that stimulates the bone marrow to make more red blood cells.

What are the applications of erythropoiesis-stimulating agents?

Erythropoiesis-stimulating agents are used to treating anemia caused by chronic kidney failure (CKD), some anticancer drugs, and certain treatments for HIV.

What is the size of the global erythropoiesis-stimulating agents market?

The global erythropoiesis-stimulating agents market is projected to generate revenue over USD 12.5 Billion by 2020.

What is the growth rate of the global erythropoiesis-stimulating agents market?

The Global Erythropoiesis Stimulating Agents Market is growing at a CAGR of 10.30% during the predicted period, 2021-2027.

What are the drivers of the global erythropoiesis-stimulating agents market?

The increasing number of patients suffering from anemic conditions induced due to cancer, HIV, and kidney failures, rise in the incidence of tumor-related anemia, Rising awareness about erythropoiesis-stimulating agent therapies are the drivers of the global erythropoiesis-stimulating agents market.

Select License

We Accept

Analyst support

After evaluating your requirements and addressing your technical problems, the expert analyst will resolve your query directly.

Customer satisfaction

According to your needs, our expert team will assist you with the capabilities, services, and proper research needs to be required and customize the report accordingly.

Inimitable expertise

Our expert team will create unrivaled reviews to provide you with a deep understanding of the reports.

Assured quality

We have created a systematic way to determine standards and satisfy your expectations.

Instant delivery

Unlike others, we provide you a great deal of instant delivery in the form of PDF/PPT/Word Doc directly to your email address within 24 hours after receiving full payment.

Privacy policy

We understand the inkling of your privacy, we will never misuse your email address.

Custom research service

We are giving you an opportunity through which you can directly ask our expert analyst to customize an exclusive study of the report to serve your research needs.

Quality & accuracy

We provide you with the accurate quality of the customized study of an exclusive report according to your research need.

Data visualization

As the business world’s growing faster every day, we understand the value of data management. We will create the reports by keeping all the visual data sets and metrics in the charts.

Information security

We truly respect your privacy and promise to keep your personal and confidential information safe and secure.